# A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

> **NCT02443324** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 175 (actual)

## Conditions studied

- Gastric Adenocarcinoma
- Adenocarcinoma of the Gastroesophageal Junction
- Non-small Cell Lung Cancer
- Carcinoma, Transitional Cell
- Biliary Tract Cancer

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02443324
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-29
- **Primary completion:** 2018-08-31
- **Final completion:** 2022-04-12
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2024-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02443324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02443324, "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02443324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*